San Francisco-based Weave Bio and Takeda have announced a collaboration to deploy Weave's AI-native regulatory automation platform across 14 of Takeda's active drug development programs in multiple global markets. The partnership covers investigational new drug (IND) submission preparation, Health Authority Question (HAQ) handling, and Response to Question (RTQ) workflows. Financial terms were not disclosed.
The Weave platform automates regulatory content preparation and lifecycle management, covering data extraction, document drafting, source traceability, and review support. In the IND submission phase, a co-authored study by scientists from both companies reported a 97% reduction in time to first draft — from approximately 100 hours to three — with measured faithfulness to source data of approximately 95% under the study's methodology. In the HAQ and RTQ deployment, the companies reported more than 100 questions processed with no extraction errors identified in the evaluated dataset, and a 68% average AI answer quality score against a stated goal of 50–70%. The co-authored research has been posted to arXiv (arXiv:2509.09738).
The collaboration preserves human accountability throughout: regulatory professionals retain responsibility for content verification and final decision-making, an approach the companies said they aligned with joint US FDA and European Medicines Agency (EMA) guiding principles on good AI practice published in January 2026.